Lv5
1240 积分 2024-08-15 加入
PSMA and Integrinαvβ3 Dual-Targeted Radioligandsfor Prostate Cancer Targeted RadionuclideTherapy
17天前
已完结
Preclinical development of a novel [68Ga]Ga-/[177Lu]Lu-labeled agent for PSMA-targeted imaging and therapy
19天前
已完结
Safety, Biodistribution, and Dosimetry of FAP and Integrin α v β 3 Dual-Targeting Radioligand 177 Lu-DOTA-FAPI-RGD: Preclinical Validation and First-in-Human Study in Patients with Advanced Adenocarcinomas
20天前
已完结
Rechallenge and Extended [ 177 Lu]Lu-PSMA Therapy in Metastatic Prostate Cancer
2个月前
已关闭
Rational Design and Development of an Acyclic Chelator H4pyox for Theranostic Radiometal Labeling under Mild Conditions
3个月前
已完结
Preclinical Investigations to Explore the Difference between the Diastereomers [177Lu]Lu-SibuDAB and [177Lu]Lu-RibuDAB toward Prostate Cancer Therapy
3个月前
已完结
Preclinical and First-in-Human Study of Carbonic Anhydrase IX–Targeting Theranostic Pair, [ 68 Ga]Ga/[ 177 Lu]Lu-NYM096, in Clear Cell Renal Cell Carcinoma
3个月前
已完结
Preclinical Evaluation of68Ga/177Lu-Labeled FAP-Targeted Peptide for Tumor Radiopharmaceutical Imaging and Therapy
3个月前
已完结
PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617
4个月前
已关闭
Clinical Implementation of Total-Body PET in China
5个月前
已完结
皖公网安备34019202002308
